Report : South & Central America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Test Type (Serology, Stool Antigen, and Urea Breath), Test Method (Laboratory Based and Point-of-Care), and End User (Hospitals, Clinics, and Diagnostic Laboratories)
At 4.8% CAGR, the South & Central America Helicobacter Pylori (H. pylori) Non-invasive Testing Market is speculated to be worth US$ 34.64 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the South & Central America helicobacter pylori (H. pylori) non-invasive testing market was valued at US$ 26.14 million in 2022 and is expected to reach US$ 34.64 million by 2028, registering an annual growth rate of 4.8% from 2022 to 2028. Increasing use of home-based POC devices and new product launches & FDA approvals for noninvasive tests are the critical factors attributed to the market expansion.
The increasing awareness of Helicobacter pylori infections such as peptic ulcers and gastritis is bringing the test diagnostics kits conveniently and quickly to the patient at home. Most clinicians recognize POC testing as a requirement for the early detection of life-threatening situations because laboratory results can be made available in real-time. In low- and middle-income countries, POC diagnostic and monitoring devices are anticipated to become universal in-home setups and at doctor's offices or hospitals.
In stool antigen testing (STA), there are two types of assays, quantitative enzyme immunoassays (EIA), which are analyzed in a laboratory setting, and qualitative immunochromatography assays (ICA), which are regularly used as a rapid test at home or in the clinic. Therefore, these factors mentioned above have increased the demand for POCs for diagnostic purposes.
On the contrary, very low diagnosis rate hurdles the growth of South & Central America helicobacter pylori (H. pylori) non-invasive testing market.
- Based on test type, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market in 2022 with a share of 45.1%, amassing US$ 11.78 million. It is projected to garner US$ 15.95 million by 2028 to expand at 5.8% CAGR during 2022–2028.
- Based on test method, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022 with a share of 75.4%, amassing US$ 19.72 million. It is projected to garner US$ 26.47 million by 2028 to expand at 5.0% CAGR during 2022–2028.
- Based on end user, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022 with a share of 58.8%, amassing US$ 15.37 million. It is projected to garner US$ 20.66 million by 2028 to expand at 5.0% CAGR during 2022–2028.
Our regional analysis states that Brazil captured 56.4% market share in 2022. It was assessed at US$ 14.75 million in 2022 and is likely to hit US$ 19.30 million by 2028, exhibiting a CAGR of 4.6% during the forecast period.
Key players dominating the South & Central America helicobacter pylori (H. pylori) non-invasive testing market are Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc.
Below are mentioned a few key market developments by major players:
- In Dec 2021, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.
- In April 2020, Meridian Bioscience, Inc. has completed the acquisition of Exalenz Bioscience Ltd., the Modiin, Israel-based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com